The HERMES Consortium aims to use genetics to gain understanding of the causes of, and potential new treatments for heart failure. 

We are working towards this in a number of ways:

Discovery
 - GWAS (genomewide association studies) to identify variants in loci that contribute to heart failure risk, prognosis and related phenotypes.







Causal investigation of risk factors
 - using Mendelian randomisation to explore whether established and emerging risk factors play causal roles in heart failure risk and prognosis.




Drug target validation
 - using Mendelian randomisation to interrogate potential effects of modulating novel drug targets on heart failure risk, prognosis and related phenotypes.